SCLC

Small Cell Lung Cancer (SCLC), also known as oat cell carcinoma, is a type of lung cancer characterized by small cells that appear oat-like under a microscope. It is known for its aggressive behavior and tendency to spread rapidly to other parts of the body. SCLC accounts for approximately 10-15% of all lung cancer cases. Due to its fast growth and early spread, it is often diagnosed at an advanced stage, making treatment more challenging.

Etiology

The primary cause of SCLC is tobacco smoking, with a vast majority of cases being directly linked to cigarette smoke. Other potential risk factors include exposure to radon gas, asbestos, and other carcinogens. However, the risk associated with these is significantly lower than that of smoking.

Pathophysiology

SCLC originates from neuroendocrine cells located in the bronchi. The cancer cells are small, with scant cytoplasm, ill-defined cell borders, and finely granular nuclear chromatin. Due to its neuroendocrine origin, SCLC can produce ectopic hormones leading to paraneoplastic syndromes such as SIADH (Syndrome of Inappropriate Antidiuretic Hormone) and Cushing's Syndrome.

Clinical Presentation

Patients with SCLC typically present with symptoms related to intrathoracic disease, such as cough, dyspnea, chest pain, and weight loss. Paraneoplastic syndromes can also be the initial presentation in some patients. Due to its aggressive nature, many patients have evidence of metastatic disease at diagnosis, with common sites including the liver, adrenal glands, bone, and brain.

Diagnosis

The diagnosis of SCLC is confirmed through histological examination of a biopsy specimen. Imaging studies, including CT scans of the chest and abdomen and MRI of the brain, are used to stage the disease and assess for metastatic spread. The Veterans Administration Lung Study Group (VALSG) staging system classifies SCLC into two stages: limited stage (disease confined to one hemithorax that can be encompassed within a single radiation field) and extensive stage (disease that has spread beyond the confines of a single radiation field).

Treatment

Treatment for SCLC typically involves a combination of chemotherapy and radiation therapy. Surgery is rarely used due to the advanced stage of disease at diagnosis. Chemotherapy regimens often include etoposide and platinum-based agents. Prophylactic cranial irradiation (PCI) is recommended for patients with limited-stage disease who have had a complete response to initial treatment, to reduce the risk of brain metastases. For extensive-stage SCLC, treatment aims to improve symptoms and prolong survival, but the prognosis remains poor.

Prognosis

The prognosis for SCLC is generally poor, with a median survival time of 2-4 months for untreated patients and about 20% surviving one year with treatment. The overall 5-year survival rate is less than 7%. Factors that can influence prognosis include the stage of disease at diagnosis, performance status of the patient, and response to treatment.

Prevention

The most effective measure to prevent SCLC is to avoid exposure to tobacco smoke. Smoking cessation programs and policies to reduce smoking prevalence are critical in reducing the incidence of SCLC.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian